Developing Therapies for Peanut Allergy

Overview

Journal Int Arch Allergy Immunol

Specialty Allergy & Immunology

Date 2014 Dec 23

PMID 25531161

Citations 5

Authors

Merima Bublin

Heimo Breiteneder

Affiliations

Soon will be listed here.

Abstract

Peanut allergy is an IgE-mediated, persisting immune disorder that is of major concern worldwide. Currently, no routine immunotherapy is available to treat this often severe and sometimes fatal food allergy. Traditional subcutaneous allergen immunotherapy with crude peanut extracts has proven not feasible due to the high risk of severe systemic side effects. The allergen-specific approaches under preclinical and clinical investigation comprise subcutaneous, oral, sublingual and epicutaneous immunotherapy with whole-peanut extracts as well as applications of hypoallergenic peanut allergens or T cell epitope peptides. Allergen-nonspecific approaches include monoclonal anti-IgE antibodies, TCM herbal formulations and Toll-like receptor 9-based immunotherapy. The potential of genetically engineered plants with reduced allergen levels is being explored as well as the beneficial influence of lactic acid bacteria and soybean isoflavones on peanut allergen-induced symptoms. Although the underlying mechanisms still need to be elucidated, several of these strategies hold great promise. It can be estimated that individual strategies or a combination thereof will result in a successful immunotherapy regime for peanut-allergic individuals within the next decade.

Citing Articles

Shrimp allergen extract immunotherapy induces prolonged immune tolerance in a gastro-food allergy mouse model.

Marhaeny H, Rohmah L, Pratama Y, Kasatu S, Miatmoko A, Addimaysqi R PLoS One. 2024; 19(12):e0315312.

PMID: 39729447 PMC: 11676511. DOI: 10.1371/journal.pone.0315312.

Development of gastro-food allergy model in shrimp allergen extract-induced sensitized mice promotes mast cell degranulation.

Marhaeny H, Pratama Y, Rohmah L, Kasatu S, Miatmoko A, Khotib J J Public Health Afr. 2023; 14(Suppl 1):2512.

PMID: 37492545 PMC: 10365647. DOI: 10.4081/jphia.2023.2512.

Human monocyte-derived type 1 and 2 macrophages recognize Ara h 1, a major peanut allergen, by different mechanisms.

Krause M, Crauwels P, Blanco-Perez F, Globisch M, Wangorsch A, Henle T Sci Rep. 2021; 11(1):10141.

PMID: 33980880 PMC: 8115286. DOI: 10.1038/s41598-021-89402-1.

Expression and activation of the steroidogenic enzyme CYP11A1 is associated with IL-13 production in T cells from peanut allergic children.

Wang M, Strand M, Lanser B, Santos C, Bendelja K, Fish J PLoS One. 2020; 15(6):e0233563.

PMID: 32497050 PMC: 7272076. DOI: 10.1371/journal.pone.0233563.

Lactobacillus buchneri S-layer as carrier for an Ara h 2-derived peptide for peanut allergen-specific immunotherapy.

Anzengruber J, Bublin M, Bonisch E, Janesch B, Tscheppe A, Braun M Mol Immunol. 2017; 85:81-88.

PMID: 28212503 PMC: 5386144. DOI: 10.1016/j.molimm.2017.02.005.

References

Peeters K, Koppelman S, van Hoffen E, van der Tas C, den Hartog Jager C, Penninks A . Does skin prick test reactivity to purified allergens correlate with clinical severity of peanut allergy?. Clin Exp Allergy. 2007; 37(1):108-15. DOI: 10.1111/j.1365-2222.2006.02628.x. View

King N, Helm R, Stanley J, Vieths S, Luttkopf D, Hatahet L . Allergenic characteristics of a modified peanut allergen. Mol Nutr Food Res. 2005; 49(10):963-71. DOI: 10.1002/mnfr.200500073. View

Mondoulet L, Dioszeghy V, Vanoirbeek J, Nemery B, Dupont C, Benhamou P . Epicutaneous immunotherapy using a new epicutaneous delivery system in mice sensitized to peanuts. Int Arch Allergy Immunol. 2010; 154(4):299-309. DOI: 10.1159/000321822. View

Zhu F, Kandimalla E, Yu D, Agrawal S . Oral administration of a synthetic agonist of Toll-like receptor 9 potently modulates peanut-induced allergy in mice. J Allergy Clin Immunol. 2007; 120(3):631-7. DOI: 10.1016/j.jaci.2007.05.015. View

de Jonge J, Ezendam J, Knippels L, Penninks A, Pieters R, Van Loveren H . Lactobacillus casei Shirota does not decrease the food allergic response to peanut extract in Brown Norway rats. Toxicology. 2008; 249(2-3):140-5. DOI: 10.1016/j.tox.2008.04.016. View

Tang D, DeVit M, Johnston S . Genetic immunization is a simple method for eliciting an immune response. Nature. 1992; 356(6365):152-4. DOI: 10.1038/356152a0. View

Leung D, Sampson H, Yunginger J, Burks Jr A, Schneider L, Wortel C . Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med. 2003; 348(11):986-93. DOI: 10.1056/NEJMoa022613. View

Lent A, Harbeck R, Strand M, Sills M, Schmidt K, Efaw B . Immunologic response to administration of standardized dog allergen extract at differing doses. J Allergy Clin Immunol. 2006; 118(6):1249-56. DOI: 10.1016/j.jaci.2006.07.055. View

Asarnoj A, Moverare R, Ostblom E, Poorafshar M, Lilja G, Hedlin G . IgE to peanut allergen components: relation to peanut symptoms and pollen sensitization in 8-year-olds. Allergy. 2010; 65(9):1189-95. DOI: 10.1111/j.1398-9995.2010.02334.x. View

10.

Roy K, Mao H, Huang S, Leong K . Oral gene delivery with chitosan--DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med. 1999; 5(4):387-91. DOI: 10.1038/7385. View

11.

Bannon G, Cockrell G, Connaughton C, West C, Helm R, Stanley J . Engineering, characterization and in vitro efficacy of the major peanut allergens for use in immunotherapy. Int Arch Allergy Immunol. 2001; 124(1-3):70-2. DOI: 10.1159/000053672. View

12.

Jones S, Burks A, Dupont C . State of the art on food allergen immunotherapy: oral, sublingual, and epicutaneous. J Allergy Clin Immunol. 2014; 133(2):318-23. DOI: 10.1016/j.jaci.2013.12.1040. View

13.

Holgate S, Chuchalin A, Hebert J, Lotvall J, Persson G, Chung K . Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy. 2004; 34(4):632-8. DOI: 10.1111/j.1365-2222.2004.1916.x. View

14.

Flinterman A, Knol E, Lencer D, Bardina L, den Hartog Jager C, Lin J . Peanut epitopes for IgE and IgG4 in peanut-sensitized children in relation to severity of peanut allergy. J Allergy Clin Immunol. 2008; 121(3):737-743.e10. DOI: 10.1016/j.jaci.2007.11.039. View

15.

Vickery B, Lin J, Kulis M, Fu Z, Steele P, Jones S . Peanut oral immunotherapy modifies IgE and IgG4 responses to major peanut allergens. J Allergy Clin Immunol. 2012; 131(1):128-34.e1-3. PMC: 3529994. DOI: 10.1016/j.jaci.2012.10.048. View

16.

Berin M, Wang W . Reduced severity of peanut-induced anaphylaxis in TLR9-deficient mice is associated with selective defects in humoral immunity. Mucosal Immunol. 2012; 6(1):114-21. PMC: 3449039. DOI: 10.1038/mi.2012.55. View

17.

Greenhawt M, MacGillivray F, Batty G, Said M, Weiss C . International study of risk-mitigating factors and in-flight allergic reactions to peanut and tree nut. J Allergy Clin Immunol Pract. 2014; 1(2):186-94. DOI: 10.1016/j.jaip.2013.01.002. View

18.

Burks A, Shin D, Cockrell G, Stanley J, Helm R, Bannon G . Mapping and mutational analysis of the IgE-binding epitopes on Ara h 1, a legume vicilin protein and a major allergen in peanut hypersensitivity. Eur J Biochem. 1997; 245(2):334-9. DOI: 10.1111/j.1432-1033.1997.t01-1-00334.x. View

19.

Novak N, Bieber T, Allam J . Immunological mechanisms of sublingual allergen-specific immunotherapy. Allergy. 2011; 66(6):733-9. DOI: 10.1111/j.1398-9995.2010.02535.x. View

20.

Gilissen L, Bolhaar S, Matos C, Rouwendal G, Boone M, Krens F . Silencing the major apple allergen Mal d 1 by using the RNA interference approach. J Allergy Clin Immunol. 2005; 115(2):364-9. DOI: 10.1016/j.jaci.2004.10.014. View